Drug facts
Semaglutide and fatigue
Quick answer
It is in the label. 11% of participants on semaglutide 2.4 mg reported it, against 5% on placebo — so 6 in 100 is what the drug itself added.
How common it was1
Fatigue appears in the label's table of reactions reported in 2% or more of participants, grouped with asthenia — a general lack of strength. The arm was 2,116 adults against 1,261 on placebo.
| Arm | Reported it |
|---|---|
| Semaglutide 2.4 mg | 11% |
| Placebo | 5% |
The placebo column matters more here than almost anywhere else in the table. Tiredness is common in anyone eating substantially less, and 5% of the placebo group reported it without any drug at all. The drug's own contribution is the gap.
What the label does not say1
It does not say when fatigue starts, how long it lasts, or whether it eases as the body adjusts — none of that is in the table, and a page that supplied it would be filling a gap with guesswork. It also does not separate fatigue from the reduced calorie intake the trial required of both arms.
What this page is not
This reports what the approved label recorded, and offers no management advice — that is your prescriber’s decision. Nor is it a measurement of a compounded vial: no compounded preparation has run a trial of its own. The full table is on side effects.
Sources
- FDA prescribing information for WEGOVY (semaglutide), section 6.1, revision 6/2026 DailyMed